Quanta Inc (fka QNTA)

[falon]

Medolife", a majority owned subsidiary of Quanta, Inc. has been very busy since the first of the year as they conducted quite a bit of research and testing of their products. They are on the verge of becoming a significant player in providing solutions to some of the world's most debilitating diseases. Medolife have made great strides thus far however they are striving to reach greater milestones as the prepare for human clinical trials in the United States and beyond.

Onward and Upward will be the trend.

January 27, 2021

Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study

After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
https://finance.yahoo.com/news/medolifes-therapeutic-scorpion-peptide-proves-135700420.html?.tsrc=rss

February 23, 2021

Medolife Rx And CURE Pharmaceutical Holding Corp. Collaborate For A Significant Increase Of Revenue

New Production Platform

Under the terms of the Collaboration and Joint Development Agreement, Medolife is investing into CURE to increase their production capabilities, while Medolife is receiving a production platform at CURE's manufacturing facility, located in Oxnard, California. This platform will be used for Medolife's pharmaceutical-grade products, such as their COVID-19 therapeutic, which is currently a US FDA Pre-Investigational New Drug (PIND #150335). In addition, Medolife is preparing for a US FDA application for their pancreatic cancer drug and a CBD topical cream to treat muscle pain, which will be produced within CURE's facility. More pharmaceutical-grade formulations are planned to follow.

Fully Licensed Facility

CURE's manufacturing facility currently holds production licenses for pharmaceuticals, nutraceuticals and cannabinoid-based products. It is also cGMP certified by the National Sanitation Foundation ("NSF") and adheres to the highest standards of quality. With the new production platform at CURE's manufacturing facility, Medolife can produce a wide variety of products, such as Medolife's COVID-19 therapeutic, cancer drugs and nutraceuticals like immune system enhancers, cosmetics, nootropics, stress relievers, and cannabinoid-based products.
https://finance.yahoo.com/news/medolife-rx-cure-pharmaceutical-holding-135600501.html?.tsrc=rss

March 09, 2021

Medolife Rx Announces Preclinical Trial Results From Toxicity Study on Lead Drug Candidate

Medolife Rx, Inc. ("Medolife"), a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today preclinical trial results on its lead drug candidate Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment for various indications including the SARS-CoV-2 (COVID-19) virus and certain cancers. The preclinical trial concluded that at maximum dose levels the product is non-toxic and safe.

The study, which was completed through a third-party contract research organization (CRO) located in California under strict medical guidelines, was conducted in two phases on BALB/c mice. The first phase was completed on 12 mice where the mice were given the drug candidate at a 26 µg/kg dose volume and monitored for 24 hours. At the conclusion of the first phase, researchers did not observe any significant abnormalities. In the second phase, the same dose of the drug candidate was administered daily over the course of 14 days where researchers also observed no significant abnormalities in clinical observations, body weight, necropsy observation, hematology, and clinical chemistry. These observations rendered a study result that the candidate is well-tolerated in mice and thus is proven safe and non-toxic.

“This study was a major first step in our clinical research programs across the world and having proven that the potential drug is safe in mice opens up the research pipeline for further trials and potential market approval,” said Medolife CEO Dr. Arthur Mikaelian. “Whenever you are working with new and novel therapeutics, both regulatory bodies and researchers want to be absolutely certain that the candidate is non-toxic before moving into human trials. This result will provide the foundation for which we can propel our research into humans, which we have already begun doing in the Dominican Republic and other countries around the world. This study data was also used in our pre-investigational new drug filing with the US Food and Drug Administration (FDA).”

This drug candidate utilizes Medolife’s patented polarization technology, which increases the potency of single molecules and complex compounds. This technology is already used in various Medolife products, ranging from supplements to drug candidates where the company is currently involved in a variety of clinical programs, including the Escozine® program. This program targets first product registration in the Dominican Republic for treatment of COVID-19 where the Company has already completed a human trial on safety and efficacy.
https://finance.yahoo.com/news/medolife-rx-announces-preclinical-trial-140000084.html?.tsrc=rss

March 16, 2021

MedolifeRx Announces Results From Efficacy Test on Polarization Technology Showing 497 Percent Increase in Efficacy of API When Polarized

Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today results from an independent efficacy test conducted on the Company’s polarization technology where the subject compound showed an increased efficacy of 497 percent when compared to its non-polarized counterpart, validating the polarization technology that is being used in most of Medolife’s clinical programs and consumer products.

The results showed that polarization of Kratom demonstrates sufficient polarizability, which is the ability of compounds to absorb photon emission through electromagnetic resonance. The ATP production in the primary human fibroblast cells of the Polarized Kratom sample is 497 percent higher than the Non-Polarized Kratom sample.

The study is important to the Company’s overall pharmaceutical and nutraceutical product research and development programs as most of the Company’s products utilize the polarization technology, which was designed to increase the potency of single molecules and complex compounds. This study further validates the technology and positions the Company for further research to increase the effectiveness of various APIs, decreasing side effects of harsh compounds as well as the raw material input of medicines and nutraceutical products.

Medolife’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company recently announced results from a toxicity study on the drug candidate that showed that at maximum dose levels the product is non-toxic and safe. The Company is seeking product registration for the treatment of COVID-19 in the Dominican Republic and has filed study data in pre-IND format with the US FDA.

https://finance.yahoo.com/news/medoliferx-announces-results-efficacy-test-130000011.html?.tsrc=rss

March 23, 2021

Medolife Rx Announces Pre-Clinical Results on Drug Candidate Escozine Showing Efficacy in Eliminating Cell Lines in Ovarian and Bladder Cancer

Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today clinical trial results conducted on its lead drug candidate Escozine® where the drug eradicated in vitro bladder (SCaBER) and ovarian (OVCAR-3 and IGR-OV1) cancer cell lines when administered for 24 hours.

The study was conducted at one of the most prestigious academic research facilities in the United States. The goal of the study was to assess the viability of human bladder and ovarian cancer cells treated with Escozine®, the Company’s polarized drug candidate derived from a small molecular peptide found in scorpions. It examined the effects of both polarized and non-polarized versions of the drug on the viability of cell walls, finding that only the polarized version had a significant effect on eliminating the cell lines in all three cancers. This highlights not only the potential of Escozine® as a treatment for cancer, but the increased efficacy and bioavailability of the drug through the polarization methodology unique to Medolife Rx. Cell lines are commonly used in in vitro model systems in many drug discovery research programs. They retain most of the genetic properties of the cancer of origin and provide researchers with an indefinite source of biological material for experimental purposes (source). This study was especially significant in that Escozine® eradicated the cell lines completely, furthering the hypothesis that the drug could eliminate cancer cells in humans completely as well.

“We could not be more pleased by the results of this research,” said Medolife CEO Dr. Arthur Mikaelian. “As we progress in our clinical research on Escozine®, where we are initially targeting product registration and approval for treatment of COVID-19, we are conducting ongoing research on its potential therapeutic benefits as a treatment for various other indications, including many types of cancer. In this study, our drug completely eliminated the cell lines of two types of cancer in three samples. These results are not just exciting, they could be the precipice for what could become an effective treatment for one of the largest health issues in the world. Beyond proving the peptides’ ability to eradicate cancer cell lines, the study also showed how effective our polarization technology is on increasing efficacy. With results like these, I could not be more confident in Escozine® as a viable treatment for a variety of health issues and we are so proud to continue to push it through clinical trials around the world.”

The Company is conducting concurrent clinical studies on Escozine® around the world in countries such as the Dominican Republic and the United States. It is seeking product registration in the Dominican Republic for treatment of COVID-19, where it recently announced positive efficacy and safety results on over 500 patients. Additionally, it has filed data on Escozine® with the US Food and Drug Administration (FDA) as a Pre-Investigational New Drug (PIND #150335) as a COVID-19 therapeutic and is hoping to receive a response in short order. Medolife utilizes a patented polarization technology in all of its clinical drug candidates and nutraceutical consumer products that increase the potency of single molecules and complex compounds.
https://finance.yahoo.com/news/medolife-rx-announces-pre-clinical-130000576.html?.tsrc=rss

March 25, 2021

Medolife Rx Completes Batch Production of Escozine® for FDA Submission

Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has completed production of a batch of its lead drug candidate Escozine® and finalized analysis of the batch, which is now ready for submission to the US Food and Drug Administration (FDA) as a part of its Pre-Investigational New Drug (PIND #150335) filing as a potential treatment for the SARS-CoV-2 (COVID-19) virus.

As a part of its previously announced filing with the FDA on Escozine®, which is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife, the Company was asked to produce a batch of the drug for further investigation by the agency. As such, Medolife produced the batch and performed analysis on it, confirming its microbiology and inclusion of its main ingredient. After successful completion of the analysis, the Company is now prepared to submit the batch according to the FDA’s request, moving the Company closer to FDA registration of the drug through the IND regulatory process. The Company hopes to complete the submission in the coming week.

https://finance.yahoo.com/news/medolife-rx-completes-batch-production-130000438.html?.tsrc=rss

March 30, 2021

Medolife Rx Furthers Expansion of Scorpion Reservation; Prepares for Mass Production of Escozine Required Upon Product Registration

Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has furthered the expansion of its scorpion reservation located in the Dominican Republic (“DR”). The first-of-its-kind location has been expanded by approximately 6,350 square meters where the Company will be able to safely and humanely cultivate scorpions of various types for the extraction of the peptides necessary to produce its lead clinical drug candidate Escozine®, which is currently awaiting product registration for the treatment of the SARS-CoV-2 (COVID-19) virus in the region.

Upon product registration in the DR, Medolife estimates demand for Escozine® could be upwards of one million doses in the first quarter after registration. The Company is actively scaling up cultivation of the peptide in order to meet this demand, as well as planning an additional expansion to the reservation in the form of a medical lab facility on the premises, which would decrease logistical costs in the Escozine® production process. Beyond its pending product registration in the DR, data on Escozine® has been submitted to the US Food and Drug Administration (FDA) through the Investigational New Drug regulatory pathway, which, if approved, would make Escozine® available to patients in the US in a matter of months.

“With a gallon of scorpion venom costing upwards of $39 million, expanding our own cultivation reservation in order to meet our internal demand for the peptides used in Escozine only made further sense,” said Medolife CEO Dr. Arthur Mikaelian. “We have one of the largest scorpion reservations in the world and this expansion only further solidifies that position. As we await our pending regulatory approvals, which we expect in short order starting within the DR, we must prepare to meet the immediate demand the approvals will render by increasing our scorpion cultivation efforts. While we plan to focus first on the Rhopalurus princeps, which is one of several types of Blue Scorpions, the expansion will also allow us to add other scorpions such as Rhopalurus abudi, whose venom has seen promising results in treating various cancers. Our next step of adding a lab facility to the location is imminent, and we will be able to fully integrate our supply chain of Escozine® and further position Medolife as an integrated global pharmaceutical and nutraceutical company.”

Medolife is dedicated to enhancing the efficiency and capacity of the reservation and adding more key personnel who are experts in scorpion reproduction and habitat. The process of extraction of the peptides does not harm the scorpions and can be repeated every 23 days, creating an ongoing value chain of peptide production. The increase in the size of the reservation allows for a reduction in the scorpion density per population and the addition of a lab in the future will provide insurance against unanticipated weather and environmental catastrophes.

https://finance.yahoo.com/news/medolife-rx-furthers-expansion-scorpion-130000236.html?.tsrc=rss

April 08, 2021

Medolife Rx Announces Positive Pre-Clinical Results Showing Up to 95 Percent Cancer Cell Apoptosis with Introduction of Lead Cancer Drug Candidate

Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today pre-clinical study results conducted at one of the leading cancer research centers in the United States showing that the Company’s lead drug candidate Escozine® caused up to 95 percent Specific Induced Apoptosis (SIA) in various types of Leukemia cancer cells. Such a result is significant not only to the Company’s ongoing clinical research, but could have tremendous effects on cancer treatments worldwide.

The study was broken into two objectives:

to evaluate the effect of Escozine® at four different concentration levels on the induction of apoptosis in five cancer cell lines: K-562: Human Chronic Myeloid Leukemia (CML); MEC-1: Human Chronic B Cell Leukemia; NAMALWA: Human Burkitt Lymphoma; RAJI: Human Burkitt Lymphoma, TP53 Wild Type; RAMOS: Human Burkitt Lymphoma, TP53 Mutated

to evaluate the effect of Escozine® at four different concentration levels on the induction of apoptosis in four Chronic Lymphocytic Leukemia (CLL) patients, two at high-risk and two at low-risk levels

The result of the first objective was that cell death was observed in all cell lines when treated with Escozine® after 48 hours of incubation. The effect on cell death was dependent on the concentration level of Escozine®, with insignificant cell death being observed in concentration levels from 10-30 percent, a variation of cell death between 5-40 percent at a 50 percent concentration of Escozine®, and a greater than 95 percent cell death in all cell lines when Escozine® was included at 100 percent concentration, with the exception of RAMOS, which showed an approximate 50 percent cell death rate.

In the second part of the study, cells were taken from four CLL human patients, two High Risk (HR) and two Low Risk (LR). The cells were introduced to Escozine® at varying concentrations, and the results showed that both HR patients reported minimal effects at concentrations of 10 percent and 30 percent of Escozine®; however, at concentrations of 50 percent, cell death occurred in approximately 50 percent of cells, and at 100 percent concentration levels, over 95 percent cell death was observed. In LR patients, similar results were observed with higher concentrations of Escozine® at 50 percent and 100 percent inclusion where high levels of cell death were observed. The results were consistent with the cell line portion of the study, confirming that Escozine at higher concentrations can cause SIA, or cell death, in greater than 95 percent of cancer cells.

“These results not only met our expectations, but exceeded them,” said Medolife CEO Dr. Arthur Mikaelian. “This study was conducted at one of the leading academic cancer research institutes in the United States under some of the most stringent guidelines. While we knew that Escozine had cancer fighting therapeutic benefits, to see over 95 percent of cancer cells killed when introduced to the drug was truly groundbreaking. Cancer is one of the leading causes of death worldwide and finding an effective therapeutic is known as the holy grail of medicine. While we still have research to conduct in order to prove this drug is an effective treatment for cancer, results like these from such a credible institution will pave the way for this further exploration.”

https://finance.yahoo.com/news/medolife-rx-announces-positive-pre-123000065.html?.tsrc=rss

April 13, 2021

Medolife Rx Submits Final Data Set to FDA for IND Filing on Lead Drug Candidate

Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has filed its final set of data requested by the US Food and Drug Administration (FDA) for its Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate Escozine® as a COVID-19 therapeutic. Along with the submission of a batch of Escozine® previously announced specifically produced for the FDA, the Company believes that this will be the last submission necessary in order to receive IND designation from the regulatory body in the United States.

Previous clinical data was submitted to the FDA including preliminary results of the safety study, which has now been expanded upon. This data, as well as the batch of Escozine® that was produced specifically for the FDA, has now been submitted. After the review of the data and barring any further inquiries or requests, the FDA will designate IND status for Escozine®, essentially allowing the drug to be distributed in the US. After such designation, the Company will pursue other clinical applications of Escozine®, including as a potential cancer therapeutic where the Company has already released positive clinical results.

“The FDA-approved therapeutic drug market is the gold standard globally and should we receive IND designation from the FDA, it would catapult our other research across the world,” said Medolife CEO Dr. Arthur Mikaelian. “Submission to the FDA is never easy, but we are generating such positive clinical trial results that we are confident the regulatory body will take notice. They have been reviewing our submission for some time, requesting various other information that we have now submitted. I believe this could be the last request ahead of approval, which would be tremendous not only for our Company, but for patients who are in need of a solution where one does not currently exist. An approval from the FDA would also propel interest from the scientific community on the potential therapeutic benefits of the natural peptides we are studying, including investment and partnership interest.”

https://finance.yahoo.com/news/medolife-rx-submits-final-data-123000200.html?.tsrc=rss